In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva to acquire worldwide rights to NeuroSearch’s Huntington’s candidate Huntexil

Executive Summary

Danish CNS biotech NeuroSearch AS has signed a preliminary agreement that grants Teva Pharmaceutical Industries Ltd.’s Swiss subsidiary Ivax International GMBH worldwide rights to its Phase III Huntington’s disease candidate Huntexil (formerly ACR16; pridopidine). The deal includes all assets and obligations, but no NeuroSearch employees will be transferred to Teva.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies